Astrazeneca

FromAstraZeneca ([email protected])
Subject (49)Enhertu approved in US for 2L HER2+ breast cancer
Preheader (128)Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
Typography
Arial
Colors
Text Analysis
Body Words182
Subject Words9
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px
X-Spam Score-5.7
Preheader OptimizedNo
Timing
Day of WeekThursday
TimeMorning

Enhertu approved in US for 2L HER2+ breast cancer

Enhertu approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
Enhertu approved in US for 2L HER2+ breast cancer